Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940242 | 0.99 | SMN1; SMN2 (0.53) | MAPTSMN1; SMN2LMNAALOX12HTT | |
| SCHEMBL2949154 | 0.99 | SMN1; SMN2 (0.53) | MAPTSMN1; SMN2LMNAALOX12HTT | |
| SCHEMBL2949155 | 0.99 | SMN1; SMN2 (0.53) | MAPTSMN1; SMN2LMNAALOX12HTT | |
| SCHEMBL2944313 | 0.95 | SMN1; SMN2 (0.56) | MAPTSMN1; SMN2LMNAALOX12HTT | |
| SCHEMBL2941566 | 0.94 | SMN1; SMN2 (0.57) | MAPTSMN1; SMN2LMNAALOX12HTT | |
| SCHEMBL2949145 | 0.94 | SMN1; SMN2 (0.57) | MAPTSMN1; SMN2LMNAALOX12HTT | |
| SCHEMBL2949142 | 0.94 | SMN1; SMN2 (0.57) | MAPTSMN1; SMN2LMNAALOX12HTT | |
| SCHEMBL2938776 | 0.92 | PTGDR2 (0.48) | MAPTSMN1; SMN2LMNAALOX12HTT | |
| SCHEMBL2941974 | 0.91 | SMN1; SMN2 (0.50) | MAPTSMN1; SMN2LMNAALOX12HTT | |
| SCHEMBL2947715 | 0.90 | SMN1; SMN2 (0.51) | MAPTSMN1; SMN2LMNAALOX12HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678826-B2 | Organic compounds for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-03-16 | — | — | US | claimed |
| EP-1891029-B1 | ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | claimed |
| US-20080200466-A1 | Organic Compounds For the Treatment of Inflammatory or Allergic Conditions | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | claimed |
| EP-1891029-A1 | ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS | Novartis AG (CH) | 2008-02-27 | — | — | EP | claimed |
| WO-2006125596-A1 | ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | claimed |
| US-7678826-B2 | Organic compounds for the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-03-16 | — | — | US | disclosed |
| EP-1891029-B1 | ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS | NOVARTIS AG (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20080200466-A1 | Organic Compounds For the Treatment of Inflammatory or Allergic Conditions | NOVARTIS AG (CH) | 2008-08-21 | — | — | US | disclosed |
| EP-1891029-A1 | ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS | Novartis AG (CH) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006125596-A1 | ORGANIC COMPOUNDS FOR THE TREATMENT OF IMFLAMMATORY OR ALLERIC CONDITIONS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200466-A1 | Organic Compounds For the Treatment of Inflammatory or Allergic Conditions | HRH2, MRGPRX2, HRH1 | MAPT 4054/4885SMN1; SMN2 3208/4885LMNA 3944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.